Poor metabolizer status at the cytochrome P450 2C9 and 2D6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia

Br J Haematol. 2003 Apr;121(1):192-4. doi: 10.1046/j.1365-2141.2003.04245_3.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Antineoplastic Agents, Alkylating / adverse effects
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 CYP2D6 / genetics*
  • Genetic Predisposition to Disease
  • Humans
  • Leukemia, Myeloid / etiology*
  • Leukemia, Myeloid / metabolism
  • Polymorphism, Genetic*
  • Radiotherapy / adverse effects
  • Topoisomerase II Inhibitors

Substances

  • Antineoplastic Agents, Alkylating
  • Topoisomerase II Inhibitors
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Cytochrome P-450 CYP2D6